The Microbiome in COPD: Emerging Potential for Microbiome-Targeted Interventions
Journal Selection Sample Work
Choosing the right journal is one of the key steps to ensuring the successful publication of a scientific article. A good match between the journal and the manuscript makes it possible to ensure that the target audience will be reached, that the scientific work will receive an adequate review, and that its visibility will be increased. This Journal Selection Report has been compiled for the manuscript entitled “The Microbiome in COPD: Emerging Potential for Microbiome-Targeted Interventions.”
Recommendations were made based on the scope of the journal, relevance to COPD and respiratory microbiome research, history of publishing similar works, indexing, impact factor, timeframes for reviewing and publication, and publication requirements. The selected journals have a good history of publishing scientific works in the field of respiratory medicine and correspond to the theme of the manuscript dedicated to the microbiome’s role in chronic obstructive pulmonary disease and microbiome-based therapy options.
The airway microbiome as a target in COPD
For much of the twentieth century the healthy lower airway was assumed to be sterile. Culture-independent sequencing has since shown that the lungs host low-density microbial communities, and that in COPD these communities tend to lose diversity and shift towards Proteobacteria such as Haemophilus and Moraxella, particularly around exacerbations. Inhaled corticosteroids and repeated antibiotic courses may themselves alter the airway microbiome, and the gut–lung axis has added the possibility that intestinal microbes influence airway inflammation.
These observations raise the question addressed by the manuscript in this sample, The Microbiome in COPD: Emerging Potential for Microbiome-Targeted Interventions. Candidate approaches range from established long-term macrolide therapy, whose benefits may partly involve microbial effects, to experimental probiotic, prebiotic and bacteriophage strategies. A review of this field is translational by nature: it links sequencing studies and mechanistic biology with clinical outcomes. That translational character is what the journal selection report has to match.
Open access, broad respiratory and high-impact: the three options
The report sets out three journals at distinct points on the impact and accessibility scale, each with a stated rationale and two examples of recent related work.
- BMC Pulmonary Medicine (BioMed Central) is the open-access option, covering prevention, diagnosis and management of pulmonary disorders along with molecular genetics, pathophysiology and epidemiology. Its supporting table names lung microbiome studies explicitly. Examples include a population-based study of home and workplace exposures in relation to inhaled corticosteroid use.
- Respiratory Medicine (W.B. Saunders, Elsevier) is the broad clinical respiratory option, whose rationale mentions emerging microbiome-based approaches. Its examples include a 2026 paper asking whether triple inhaled therapy should start earlier in COPD.
- American Journal of Respiratory and Critical Care Medicine (American Thoracic Society) is the high-impact option, publishing human, animal and in vitro research on respiratory pathophysiology. Its examples — on IL-33 and its receptor in the lower airways, and on neuroendocrine cells in eosinophilic COPD — show its appetite for mechanistic work.
Numbers that separate the microbiome shortlist
The comparator values below are as reported in this sample. They differ in places from figures reported for the same journals in other samples prepared at different times, which illustrates why metrics must be rechecked at submission.
| Parameter | BMC Pulm Med | Respir Med | Am J Respir Crit Care Med |
|---|---|---|---|
| Impact factor | 3.1 | 3.3 | 21.7 |
| Review duration | 14 days | 65 days | 1.1 months |
| Acceptance rate | 15–20% | 21% | 10% |
| APC | USD 2,890 | standard open-access fees apply | not stated |
| Display items | no strict limit | 4–6 combined | 4–8 combined |
| References | 30–50 | 30–40 | 40–50 |
The reference ranges are particularly relevant for a review: a microbiome review drawing on sequencing, mechanistic and clinical studies can easily outgrow a 30–40 reference allowance, so the author may need to prioritise recent and high-quality sources.
Article-processing arrangements also differ. BMC Pulmonary Medicine is fully open access with a stated charge; Respiratory Medicine is recorded only as "standard open-access fees apply", meaning the fee depends on whether the author chooses the open-access route; and no charge is stated for the American Thoracic Society journal. For a microbiome review that may be read by microbiologists, immunologists and pulmonologists in many countries, free availability can widen its readership, but it should be weighed against the visibility that a high-impact society journal brings.
Choosing a home for a translational microbiome review
If the review's strength lies in mechanism — how dysbiosis drives inflammation and how specific interventions might reverse it — the American Journal of Respiratory and Critical Care Medicine is the natural aspiration, though a reported 10% acceptance rate and frequent commissioning of reviews at journals of this level suggest a pre-submission enquiry. If the emphasis is clinical, Respiratory Medicine reaches practising pulmonologists. BMC Pulmonary Medicine offers rapid reported review and unrestricted access, useful when the goal is wide readership.
The seven-question appendix explains what a journal selection report is and what a comparison contains, which makes the document accessible to first-time authors. One improvement worth making when adapting this sample is to keep the job-sheet keywords strictly about the manuscript; here the list mixes topic terms with words such as journal names and "manuscript submission". Topic keywords drive the search for comparable published articles. Pubrica's journal selection service produces these reports, and literature review and gap analysis can strengthen the evidence base of a review before submission, with journal submission support completing the process.
Questions about this sample
Why is the American Journal of Respiratory and Critical Care Medicine included for a microbiome review?
The report notes that it publishes human, animal and in vitro research on respiratory pathophysiology, including COPD pathogenesis and the lung microbiome. As reported in the sample, its impact factor is 21.7 and its acceptance rate about 10 percent, so it suits a review with a strong mechanistic and translational argument.
Which journal explicitly mentions lung microbiome research in its rationale?
BMC Pulmonary Medicine. Its rationale in the supporting table states that it publishes open-access research on respiratory diseases including COPD, pulmonary infections and lung microbiome studies, making it relevant for microbiome-targeted interventions. The sample reports a review time of about 14 days.
Why do the figures for Respiratory Medicine differ from other Pubrica samples?
Each journal selection report reflects metrics at the time it was prepared, and sources for acceptance rates and review times vary. Different samples may therefore record different values for the same journal. Authors should always confirm current impact factors, charges and editorial statistics on the journal's own website.
What microbiome-targeted interventions might a COPD review discuss?
Reviews in this area commonly consider long-term macrolide antibiotics, probiotics and prebiotics, approaches acting through the gut–lung axis and experimental bacteriophage therapy. The evidence base differs greatly between them, so a good review distinguishes established clinical practice from early-stage research rather than presenting all options as equally mature.
Give yourself the academic edge today
Each order includes
- On-time delivery or your money back
- A fully qualified writer in your subject
- In-depth proofreading by our Quality Control Team
- 100% confidentiality, the work is never re-sold or published
- Standard 7-day amendment period
- A paper written to the standard ordered
- A detailed plagiarism report
- A comprehensive quality report
Enquire Now
